New option extends dosing from two to four weeks,
reducing medical visits and improving patient convenience

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 15 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 January 2021 07:03:04 UTC